NCT03020602View on ClinicalTrials.gov

BPM31510 in Treating Patients With Recurrent High-Grade Glioma Previously Treated With Bevacizumab

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 4, 2017

Primary Completion Date

April 4, 2019

Study Completion Date

June 26, 2021

Conditions
GliosarcomaRecurrent GlioblastomaAstrocytoma of BrainGlioblastoma
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

DRUG

Ubidecarenone Injectable Nanosuspension

Given IV

Trial Locations (1)

94304

Stanford University, School of Medicine, Palo Alto

All Listed Sponsors
lead

Seema Nagpal

OTHER

NCT03020602 - BPM31510 in Treating Patients With Recurrent High-Grade Glioma Previously Treated With Bevacizumab | Biotech Hunter | Biotech Hunter